Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and Food-effect of RJ4287 in Healthy Volunteers
NCT05921006Phase 1Unknown
- Sponsor
- Nanjing Ruijie Pharmaceutical Technology
- Start
- Jun 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and dyslipidemia comparing RJ4287 Tablets with Placebo (2 arms). Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 1 month. Status: unknown.
02
Drugs
rj4287
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)dyslipidemia
Beyond the preview
Go deeper on NCT05921006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05921006.